A high-quality portfolio of services for patients in diverse clinical situations
Foundation Medicine’s high-quality portfolio of comprehensive genomic profiling services helps healthcare professionals to optimise and personalise treatment strategies for patients in diverse clinical situations:1–4
All of Foundation Medicine's services use our leading comprehensive genomic profiling approach, wich broadly analyses the tumour genome to identify clinically relevant alterations and potentially expands patients' treatment options.5-10
As our understanding of cancer evolves, so do our tests
Our continuously growing genomic database currently includes over 200,000 genomic profiles in over 150 common and rare tumour subtypes. Advanced bioinformatics interpret the data, including rare and complex alterations, to generate powerful insights.11 Our tests are constantly evolving to capture the most clinically relevant genomic alterations so you stay up-to-date and the latest treatment options can be considered.1,6
FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed March 2019).
FoundationOne®CDx FDA Approval, 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed March 2019).
FoundationOne®Liquid Technical Specifications, 2018. Available at: https://www.foundationmedicine.com/genomic-testing/foundation-one-liquid (Accessed March 2019).
FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019).
Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
Rankin A et al. Oncologist 2016; 21: 1306–1314.
Ross JS et al. Cancer 2016; 122: 2654–2662.
Suh JH et al. Oncologist 2016; 21: 684–691.
Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
Foundation Insights. Available at: https://www.foundationmedicine.com/insights-and-trials/foundation-insights (Accessed March 2019).